Organoids in biomedicine: Bridging innovation, disease modeling, and regulatory transformation

Organoids, which are three-dimensional cultures derived from pluripotent or adult stem cells, meticulously mimic human organ architecture and function, revolutionizing biomedical research. Patient-derived organoids have emerged as powerful tools in disease modeling, particularly in cancer research. For instance, in the case of colorectal cancer, organoids are developed from tumor tissues of patients, allowing for drug sensitivity tests that can inform personalized treatment plans, as seen in the case of a patient responding well to specific chemotherapy drugs. In addition, organoids have been used to study regenerative mechanisms, such as the repair of intestinal stem cells post-radiation, showcasing their versatility in biomedical research. In drug development, they facilitate screening for efficacy and toxicity, with applications in testing poly-ADP ribose polymerase (PARP) inhibitors and cosmetic ingredients, while aligning with ethical imperatives as the U.S. Food and Drug Administration (FDA) plans to phase out animal testing for certain drugs by 2025. In addition, organoids show promise in regenerative medicine, such as endometrial and retinal regeneration, and bone tissue engineering. Despite challenges such as variable culture conditions, limited vascularization, and high costs, standardizing protocols and integrating microenvironmental factors will enhance their clinical utility, driving a shift toward human-centric therapeutic advancements.